MCID: EST002
MIFTS: 44

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 11 14 16

Classifications:



External Ids:

Disease Ontology 11 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

Disease Ontology: 11 A breast cancer that is characterized by the absence of estrogen receptors.

MalaCards based summary: Estrogen-Receptor Negative Breast Cancer is related to hereditary breast cancer and body mass index quantitative trait locus 11. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Gemcitabine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are Decreased viability and Decreased viability in pancreas lineage

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 hereditary breast cancer 30.6 CDH1 BRCA2 BRCA1
2 body mass index quantitative trait locus 11 29.9 TP53 STAT3 MIR10B H2AC18 ESR1 CYP19A1
3 breast cancer 29.8 TP53 STAT3 PGR MYC MIR373 MIR10B
4 colonic benign neoplasm 29.3 TP53 STAT3 MYC H2AC18 ESR1 ERBB2
5 estrogen-receptor positive breast cancer 29.3 TP53 STAT3 PGR ORAI3 MYC H2AC18
6 peripheral nervous system disease 29.2 TP53 STAT3 MYC H2AC18 ESR1 ERBB2
7 colorectal cancer 28.5 TP53 STAT3 PGR MYC MIR10B H2AC18
8 ovarian cancer 28.5 TP53 STAT3 PGR MYC MIR10B H2AC18
9 uterine corpus adenosarcoma 10.4 PGR ESR1
10 adult cystic nephroma 10.4 PGR ESR1
11 vagina leiomyosarcoma 10.4 PGR ESR1
12 vulvar benign neoplasm 10.4 PGR ESR1
13 adenosquamous breast carcinoma 10.4 TP53 PGR
14 lipid-rich breast carcinoma 10.4 PGR ERBB2
15 her2-receptor negative breast cancer 10.4 PGR ERBB2
16 nipple carcinoma 10.4 PGR ESR1 ERBB2
17 breast mucinous cystadenocarcinoma 10.4 PGR ESR1 ERBB2
18 breast fibroadenosis 10.4 PGR ESR1 ERBB2
19 bulbospinal polio 10.4 PGR ESR1 ERBB2
20 spinal polio 10.4 PGR ESR1 ERBB2
21 glycogen-rich clear cell breast carcinoma 10.4 PGR ESR1 ERBB2
22 breast cystic hypersecretory carcinoma 10.4 PGR ESR1 ERBB2
23 oncocytic breast carcinoma 10.4 PGR ESR1 ERBB2
24 breast squamous cell carcinoma 10.4 PGR ESR1 ERBB2
25 breast papillary carcinoma 10.4 PGR ESR1 ERBB2
26 malignant spiradenoma 10.4 TP53 ESR1
27 cervical adenocarcinoma 10.4 TP53 PGR ESR1
28 progesterone resistance 10.4 PGR ESR1
29 hereditary site-specific ovarian cancer syndrome 10.4 BRCA2 BRCA1
30 ovary transitional cell carcinoma 10.4 BRCA2 BRCA1
31 lipid-rich carcinoma 10.4 PGR ESR1 ERBB2
32 breast adenoid cystic carcinoma 10.4 PGR ESR1 ERBB2
33 progesterone-receptor negative breast cancer 10.4 PGR ESR1 ERBB2
34 bartholin's gland adenoma 10.4 TP53 PGR ESR1
35 bartholin's gland benign neoplasm 10.4 TP53 PGR ESR1
36 vestibular gland benign neoplasm 10.4 TP53 PGR ESR1
37 glycogen-rich carcinoma 10.4 PGR ERBB2
38 microglandular adenosis 10.4 PGR ESR1 ERBB2
39 apocrine adenosis of breast 10.4 TP53 ERBB2
40 apocrine sweat gland neoplasm 10.4 PGR ESR1 ERBB2
41 intraductal papilloma 10.4 PGR ESR1 ERBB2
42 bizarre leiomyoma 10.4 TP53 PGR ESR1
43 endometrial squamous cell carcinoma 10.4 TP53 PGR
44 diffuse peritoneal leiomyomatosis 10.3 PGR ESR1 CYP19A1
45 peritoneal benign neoplasm 10.3 PGR ESR1 CYP19A1
46 cervical adenosarcoma 10.3 TP53 PGR ESR1
47 endometrial stromal tumor 10.3 PGR H2AC18 ESR1
48 urethral benign neoplasm 10.3 TP53 PGR ESR1
49 cancerophobia 10.3 BRCA2 BRCA1
50 49, xxxxy syndrome 10.3

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.98 EGFR
2 Decreased viability GR00055-A-2 9.98 EGFR
3 Decreased viability GR00221-A-1 9.98 AKT1 CDH1 EGFR ESR1 MYC
4 Decreased viability GR00221-A-2 9.98 AKT1 ESR1
5 Decreased viability GR00221-A-3 9.98 AKT1 MYC
6 Decreased viability GR00221-A-4 9.98 AKT1 EGFR ESR1
7 Decreased viability GR00249-S 9.98 AKT1 MYC
8 Decreased viability GR00301-A 9.98 CDH1
9 Decreased viability GR00386-A-1 9.98 ESR1
10 Decreased viability GR00402-S-2 9.98 CDH1 ESR1 MYC
11 Decreased viability in pancreas lineage GR00235-A 8.92 CCND1 GPER1 PGR TP53

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.43 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
2 homeostasis/metabolism MP:0005376 10.4 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
3 neoplasm MP:0002006 10.37 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
4 endocrine/exocrine gland MP:0005379 10.37 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
5 growth/size/body region MP:0005378 10.36 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
6 muscle MP:0005369 10.27 AKT1 BRCA1 CYP19A1 EGFR ERBB2 ESR1
7 cellular MP:0005384 10.25 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
8 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 CCND1 CDH1 CYP19A1 EGF
9 embryo MP:0005380 10.22 AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
10 cardiovascular system MP:0005385 10.22 AKT1 BRCA1 CCND1 CDH1 CYP19A1 EGFR
11 immune system MP:0005387 10.21 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
12 limbs/digits/tail MP:0005371 10.2 BRCA1 BRCA2 EGFR ERBB2 ESR1 GPER1
13 no phenotypic analysis MP:0003012 10.18 CDH1 EGFR ESR1 GPER1 MIR10B MYC
14 liver/biliary system MP:0005370 10.16 AKT1 CYP19A1 EGFR ESR1 GPER1 MYC
15 adipose tissue MP:0005375 10.14 AKT1 BRCA1 CYP19A1 EGFR ESR1 MYC
16 reproductive system MP:0005389 10.13 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
17 skeleton MP:0005390 10 AKT1 BRCA1 BRCA2 CCND1 CYP19A1 EGFR
18 respiratory system MP:0005388 9.92 AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
19 hematopoietic system MP:0005397 9.77 AKT1 BRCA1 BRCA2 CCND1 CYP19A1 EGFR
20 integument MP:0010771 9.47 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2, Phase 3 95058-81-4, 122111-03-9 60750
2
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
3 Antiviral Agents Phase 2, Phase 3
4 Anti-Infective Agents Phase 2, Phase 3
5
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
6
Lenograstim Approved, Investigational Phase 2 135968-09-1
7
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
8
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
9
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
10
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
11
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
12
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
13
Trastuzumab Approved, Investigational Phase 2 180288-69-1
14
Medroxyprogesterone acetate Approved, Investigational Phase 2 520-85-4, 71-58-9 6279 10631
15
Busulfan Approved, Investigational Phase 2 55-98-1 2478
16
Melphalan Approved Phase 2 148-82-3 4053 460612
17
Aldesleukin Approved Phase 2 110942-02-4
18
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
19
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
20
Sargramostim Approved, Investigational Phase 2 123774-72-1
21
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
22
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
23
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
24
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
25
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
26
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
27
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
28
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
29
Epirubicin Approved Phase 2 56420-45-2 41867
30
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
31
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
32
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
35
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
36
Saracatinib Investigational Phase 2 379231-04-6 10302451
37
Veliparib Investigational Phase 2 912444-00-9 11960529
38
Molgramostim Investigational Phase 2 99283-10-0
39
Entinostat Investigational Phase 2 209783-80-2 4261
40 Immunoglobulins, Intravenous Phase 2
41 Immunoglobulins Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Antibodies, Monoclonal Phase 2
44 Antibodies Phase 2
45 Folic Acid Antagonists Phase 2
46 Folate Phase 2
47 Vitamin B9 Phase 2
48 Estrogen Receptor Modulators Phase 2
49 Vitamin B Complex Phase 2
50 Dermatologic Agents Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel;Carboplatin;Gemcitabine
2 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer Active, not recruiting NCT01805076 Phase 3
3 Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Unknown status NCT01372579 Phase 2 eribulin mesylate;carboplatin
4 A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer Completed NCT00559507 Phase 2 saracatinib
5 Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib Completed NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
6 A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
7 MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
8 A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
9 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
10 An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer Completed NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
11 A Phase 2 Study of VLS-101 in Patients With Solid Tumors Recruiting NCT04504916 Phase 2 Zilovertamab vedotin
12 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Active, not recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
13 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Active, not recruiting NCT01471106 Phase 2 Dasatinib
14 A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC) Suspended NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
15 A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
16 GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response Terminated NCT01234532 Phase 2 entinostat;anastrozole
17 A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
18 A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer Withdrawn NCT01100489 Phase 2
19 Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
20 Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
21 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
22 Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative Terminated NCT01217411 Phase 1 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
23 Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer Recruiting NCT05541367
24 A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α Terminated NCT00503841 erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

Organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

MalaCards : Breast, Brain, Lymph Node, Prostate, Colon, Lung, Ovary

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 355)
# Title Authors PMID Year
1
Burden of lymphedema in long-term breast cancer survivors by race and age. 62
36223240 2022
2
Everolimus for Estrogen Receptor-negative Breast Cancer Prevention: A Journey Begun? 62
36453053 2022
3
Twist alters the breast tumor microenvironment via choline kinase to facilitate an aggressive phenotype. 62
36136285 2022
4
Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis. 62
36156086 2022
5
RE: Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. 62
35377448 2022
6
EGF-Dependent Activation of ELK1 Contributes to the Induction of CLDND1 Expression Involved in Tight Junction Formation. 62
35892692 2022
7
ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients. 62
35486908 2022
8
Uncoiling the link between STIM1 and metastatic pathways in estrogen receptor negative breast cancer cells. 62
35180509 2022
9
Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer. 62
35508495 2022
10
Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models. 62
35404400 2022
11
Two distinct mechanisms underlie estrogen-receptor-negative breast cancer susceptibility at the 2p23.2 locus. 62
34803163 2022
12
27-Hydroxycholesterol Binds GPER and Induces Progression of Estrogen Receptor-Negative Breast Cancer. 62
35326671 2022
13
Nuclear Localization of Fibroblast Growth Factor Receptor 1 in Breast Cancer Cells Interacting with Cancer Associated Fibroblasts. 62
35419302 2022
14
Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. 62
34508608 2022
15
Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. 62
35151363 2022
16
The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study. 62
35747466 2022
17
Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. 62
35847859 2022
18
Investigation of Chemopreventive and Antiproliferative Potential of Dicliptera roxburghiana. 62
34991410 2022
19
Perfluorooctanoic acid (PFOA) as a stimulator of estrogen receptor-negative breast cancer MDA-MB-231 cell aggressiveness: Evidence for involvement of fatty acid 2-hydroxylase (FA2H) in the stimulated cell migration. 62
35370244 2022
20
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. 62
34244306 2021
21
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. 62
34042955 2021
22
The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells. 62
33840002 2021
23
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. 62
33230261 2021
24
Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. 62
33810567 2021
25
A Population-Based Study of Genes Previously Implicated in Breast Cancer. 62
33471974 2021
26
Stratification of Estrogen Receptor-Negative Breast Cancer Patients by Integrating the Somatic Mutations and Transcriptomic Data. 62
33613637 2021
27
Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells. 62
35018235 2021
28
Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer. 62
33968724 2021
29
Uncovering Tumor-Stroma Inter-relationships Using MALDI Mass Spectrometry Imaging. 62
32870688 2020
30
Polycystic ovary syndrome is causally associated with estrogen receptor-positive instead of estrogen receptor-negative breast cancer: a Mendelian randomization study. 62
32413428 2020
31
Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining. 62
32216630 2020
32
GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. 62
32047936 2020
33
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets. 62
32942528 2020
34
Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. 62
32878860 2020
35
Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. 62
32471192 2020
36
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. 62
32300202 2020
37
Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer. 62
32218854 2020
38
G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. 62
32034133 2020
39
Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. 62
32656076 2020
40
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. 62
33194937 2020
41
Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. 62
31950839 2020
42
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. 62
32964118 2020
43
Retraction: Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. 62
32218596 2020
44
High expression of soluble CD155 in estrogen receptor-negative breast cancer. 62
31372841 2020
45
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. 62
31875548 2019
46
Galbanic acid: Induced antiproliferation in estrogen receptor-negative breast cancer cells and enhanced cellular redox state in the human dermal fibroblasts. 62
31576639 2019
47
GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. 62
31694641 2019
48
β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. 62
31290053 2019
49
Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. 62
31190337 2019
50
Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. 62
31402953 2019

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 TP53 STAT3 MYC ESR1 ERBB2 EGFR
2 13.83 TP53 STAT3 PGR MYC H2AC18 GPER1
3
Show member pathways
13.81 AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
4
Show member pathways
13.78 TP53 STAT3 MYC ESR1 ERBB2 EGFR
5
Show member pathways
13.62 TP53 STAT3 MYC ERBB2 EGFR EGF
6
Show member pathways
13.56 AKT1 BRCA1 BRCA2 CCND1 EGF EGFR
7
Show member pathways
13.48 TP53 STAT3 ERBB2 EGFR EGF CCND1
8
Show member pathways
13.45 STAT3 MYC ESR1 ERBB2 EGFR EGF
9
Show member pathways
13.15 TP53 ESR1 ERBB2 EGFR EGF AKT1
10
Show member pathways
13.06 PGR MYC H2AC18 ESR1 EGFR EGF
11
Show member pathways
13.05 TP53 MYC EGFR EGF CCND1 BRCA1
12 12.93 STAT3 PGR MYC ESR1 ERBB2 EGFR
13
Show member pathways
12.92 TP53 STAT3 MYC CCND1 AKT1
14
Show member pathways
12.9 TP53 MYC H2AC18 ESR1 BRCA1
15
Show member pathways
12.87 TP53 MYC H2AC18 EGFR EGF CCND1
16
Show member pathways
12.83 STAT3 MYC ESR1 EGFR CCND1
17
Show member pathways
12.77 AKT1 EGF EGFR ERBB2 ESR1
18 12.77 AKT1 BRCA1 CCND1 CDH1 EGF EGFR
19
Show member pathways
12.76 TP53 STAT3 EGFR EGF AKT1
20
Show member pathways
12.73 TP53 STAT3 MYC EGFR EGF AKT1
21
Show member pathways
12.71 BRCA1 BRCA2 CCND1 ESR1 MYC TP53
22
Show member pathways
12.69 TP53 STAT3 MYC ERBB2 EGFR AKT1
23
Show member pathways
12.64 TP53 STAT3 MYC ERBB2 EGFR EGF
24
Show member pathways
12.56 TP53 STAT3 MYC ERBB2 EGFR EGF
25
Show member pathways
12.54 TP53 STAT3 ESR1 ERBB2 CDH1 CCND1
26 12.53 TP53 MYC CDH1 CCND1 AKT1
27
Show member pathways
12.52 STAT3 ESR1 EGFR EGF CCND1 AKT1
28 12.51 TP53 MYC EGFR EGF AKT1
29
Show member pathways
12.5 TP53 ERBB2 EGFR AKT1
30
Show member pathways
12.48 PGR MYC ESR1 CCND1 BRCA1
31
Show member pathways
12.47 AKT1 BRCA1 ESR1 STAT3
32
Show member pathways
12.46 STAT3 ERBB2 EGFR EGF CDH1
33
Show member pathways
12.42 AKT1 CCND1 EGF EGFR ERBB2 ESR1
34
Show member pathways
12.4 AKT1 CCND1 MYC STAT3
35 12.4 ERBB2 EGFR EGF CCND1 AKT1
36
Show member pathways
12.39 STAT3 MYC EGFR EGF AKT1
37
Show member pathways
12.34 TP53 MYC CCND1 AKT1
38
Show member pathways
12.34 TP53 MYC ERBB2 EGFR CCND1 AKT1
39
Show member pathways
12.3 TP53 CCND1 BRCA1 AKT1
40
Show member pathways
12.26 AKT1 CCND1 EGF EGFR ERBB2 STAT3
41
Show member pathways
12.23 TP53 MYC CCND1 BRCA1 AKT1
42
Show member pathways
12.22 STAT3 ERBB2 EGFR EGF CCND1 AKT1
43 12.22 TP53 STAT3 MYC EGFR EGF CDH1
44 12.2 AKT1 EGFR ERBB2 TP53
45
Show member pathways
12.2 PGR ESR1 ERBB2 EGFR EGF
46
Show member pathways
12.14 ERBB2 EGFR EGF AKT1
47
Show member pathways
12.14 TP53 STAT3 ERBB2 EGFR AKT1
48 12.1 TP53 MYC EGFR CCND1
49
Show member pathways
12.09 MYC ERBB2 EGFR EGF AKT1
50 12.07 STAT3 MYC EGFR CDH1 CCND1 AKT1

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.47 TP53 MYC ESR1 EGFR BRCA2 BRCA1
2 nuclear ubiquitin ligase complex GO:0000152 9.26 BRCA2 BRCA1

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.53 AKT1 BRCA1 EGFR ESR1 GPER1 MYC
2 positive regulation of cell population proliferation GO:0008284 10.32 AKT1 CCND1 EGF EGFR ERBB2 GPER1
3 regulation of cell cycle GO:0051726 10.26 BRCA1 CCND1 GPER1 STAT3 TP53
4 positive regulation of protein phosphorylation GO:0001934 10.26 GPER1 ERBB2 EGFR CCND1 AKT1
5 positive regulation of DNA-templated transcription GO:0045893 10.26 TP53 STAT3 MYC ESR1 EGFR EGF
6 negative regulation of gene expression GO:0010629 10.17 AKT1 ESR1 GPER1 PGR STAT3 TP53
7 response to estradiol GO:0032355 10.14 STAT3 ESR1 CYP19A1 CCND1
8 epidermal growth factor receptor signaling pathway GO:0007173 10.11 EGFR EGF AKT1
9 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 10.1 EGFR CCND1 AKT1
10 cellular response to epidermal growth factor stimulus GO:0071364 10.1 ERBB2 EGFR AKT1
11 cellular response to estradiol stimulus GO:0071392 10.08 GPER1 ESR1 EGFR
12 cellular response to ionizing radiation GO:0071479 10.06 TP53 BRCA2 BRCA1
13 positive regulation of epithelial cell proliferation GO:0050679 10.04 MYC ERBB2 EGFR EGF
14 response to gamma radiation GO:0010332 10.02 BRCA2 MYC TP53
15 chromosome organization GO:0051276 9.97 TP53 MYC BRCA2
16 response to X-ray GO:0010165 9.95 TP53 CCND1 BRCA2
17 positive regulation of miRNA transcription GO:1902895 9.95 TP53 STAT3 MYC EGFR
18 mammary gland alveolus development GO:0060749 9.93 ESR1 EGF CCND1
19 cellular response to indole-3-methanol GO:0071681 9.9 CDH1 BRCA1
20 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.89 TP53 ESR1
21 positive regulation of gene expression GO:0010628 9.89 TP53 STAT3 PGR MYC GPER1 ERBB2
22 intracellular steroid hormone receptor signaling pathway GO:0030518 9.85 PGR GPER1 ESR1
23 steroid hormone mediated signaling pathway GO:0043401 9.83 PGR GPER1 ESR1
24 ERBB2-EGFR signaling pathway GO:0038134 9.8 EGF EGFR ERBB2
25 chordate embryonic development GO:0043009 9.79 BRCA2 BRCA1
26 response to UV-A GO:0070141 9.63 AKT1 CCND1 EGFR
27 cell population proliferation GO:0008283 9.28 TP53 STAT3 EGFR EGF CCND1 BRCA2

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.37 TP53 STAT3 PGR ESR1 ERBB2 EGFR
2 steroid binding GO:0005496 9.8 PGR GPER1 ESR1
3 enzyme binding GO:0019899 9.8 TP53 PGR ESR1 EGFR CCND1 BRCA1
4 protein phosphatase binding GO:0019903 9.76 TP53 STAT3 ERBB2 EGFR
5 nuclear estrogen receptor activity GO:0030284 9.56 ESR1 GPER1
6 nitric-oxide synthase regulator activity GO:0030235 9.1 ESR1 EGFR AKT1

Sources for Estrogen-Receptor Negative Breast Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....